Regencell Bioscience Holdings (RGC) Debt Ratio (2020 - 2025)
Regencell Bioscience Holdings' (RGC) quarterly Debt Ratio came in at 0.0 in Q4 2025, down 92.03% quarter-over-quarter from 0.0 in Q2 2025.
Powered by 
Analysis
Regencell Bioscience Holdings (RGC) Debt Ratio (2020 - 2025) Analysis & Trends
Regencell Bioscience Holdings (RGC) has reported Debt Ratio for 3 consecutive years, with 0.0 the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Debt Ratio changed N/A year-over-year to 0.0; the trailing twelve-month figure through Dec 2025 stood at 0.0 (changed N/A YoY), and the FY2025 full-year result was 0.0, changed N/A from the prior year.
- Debt Ratio slipped to 0.0 in Q4 2025 per RGC's latest filing, from 0.0 in the prior quarter.
- Across five years, Debt Ratio topped out at 0.0 in Q2 2023 and bottomed at 0.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.38 Bn | 624.62 Bn | 17.26 Bn | 0.30 |
| 2 | AbbVie | 443.13 Bn | 436.56 Bn | 12.70 Bn | 0.52 |
| 3 | Merck | 365.40 Bn | 358.26 Bn | 12.21 Bn | 0.42 |
| 4 | Novartis Ag | 266.79 Bn | 259.10 Bn | 11.24 Bn | 0.08 |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 0.31 |
| 6 | Sanofi | 52.39 Bn | 45.00 Bn | 10.79 Bn | 0.17 |
| 7 | Revolution Medicines | 43.92 Bn | 43.92 Bn | - | - |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn | 0.00 |
| 9 | United Therapeutics | 21.55 Bn | 18.88 Bn | 683.80 Mn | - |
| 10 | Regencell Bioscience Holdings | 75.67 Mn | 73.31 Mn | - | 0.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 0.00 |
| Jun 30, 2025 | 0.00 |
| Jun 30, 2023 | 0.00 |
| Jun 30, 2020 | 5.97 |